Drug Profile
Research programme: brain injury therapeutics - SOL Global Investments
Alternative Names: SCY 001P; SCY 002PLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Scythian Biosciences
- Developer SOL Global Investments
- Class Cannabinoids; Neuroprotectants
- Mechanism of Action Cannabinoid receptor CB2 agonists; Fatty acid amide hydrolase inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Brain injuries in Canada
- 05 Apr 2019 SOL Global Investments Corp files two patent applications for Traumatic brain injuries prior to April 2019
- 05 Apr 2019 SOL Global Investments Corp announces intention to submit IND with the US FDA for Traumatic brain injury (TBI)